Overview: TIMP-1 TestIntroduction: The TIMP-1 Test measures TIMP-1 levels to assess cancer progression or fibrosis, helping diagnose conditions causing abnormal growth or liver damage. Affecting 1 in 100 people with liver disease, TIMP-1 elevation poses diagnostic challenges due to overlap with other conditions. Following 2023 American Association for the Study of Liver Diseases (AASLD) guidelines, it uses ELISA for high accuracy, supporting biochemistry screening. This test is essential for diagnosis, treatment planning, and improving outcomes in hepatology.
Other Names: TIMP-1 Level Test, Fibrosis Marker Assay.
FDA Status: Laboratory-developed test (LDT), meeting biochemistry standards for diagnostic reliability.
Historical Milestone: TIMP-1 testing began in the 1990s with research by Murphy, who linked it to fibrosis. ELISA advancements by R&D Systems improved detection, surpassing earlier Western blot methods.
Purpose: Measures TIMP-1 levels to assess cancer progression or fibrosis, guides therapy or monitoring, and evaluates patients with liver issues, aiming to manage disease.
Test Parameters: TIMP-1 levels
Pretest Condition: No special preparation required. Collect serum or plasma. Report history of liver or cancer issues.
Specimen: Serum (SST, 2-5 mL), Plasma (NaHep, 2-4 mL); 2 mL serum in SST. Transport in a biohazard container.
Sample Stability at Room Temperature: 6 hours
Sample Stability at Refrigeration: 1 week
Sample Stability at Frozen: 1 month
Medical History: Document cancer history or liver issues. Include current medications or family history.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., cirrhosis), and sample collection risks.
Procedural Considerations: Uses ELISA to measure levels, requiring labs with plate readers. Results available in 1-2 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample hemolysis or contamination can affect results. Medications may alter levels, requiring correlation.
Clinical Significance: Elevated levels suggest cancer or fibrosis, guiding therapy. Early treatment might prevent progression, while untreated cases lead to worsening. Normal levels may require other tests.
Specialist Consultation: Consult a hepatologist or oncologist for interpretation.
Additional Supporting Tests: Liver function tests, biopsy, or imaging to confirm diagnosis.
Test Limitations: Non-specific for cause; correlation with clinical status needed. False positives possible with inflammation.
References: AASLD Guidelines, 2023; Journal of Hepatology, Murphy G, 2022.
